The aim of our study was to evaluate if both spectroscopy and perfusion magnetic resonance (MR) imaging are necessary to differentiate high grade gliomas from low grade tumour, or if only one of these techniques is sufficient. Sixty-five patients with cerebral glioma were retrospectively evaluated. All patients were studied both with spectroscopy and perfusion imaging. In 43 cases histological examination showed a high grade glioma while a low grade glioma was found in 22 patients. For every patient spectroscopic maximum Cho/NAA ratio and lactate presence was established maximum relative CBV value was evaluated by perfusion MR. Both for Cho/NAA and rCBV threshold values were obtained by means of ROC curves. Then diagnostic sensitivity and specificity for high grade gliomas identification was evaluated for spectroscopic data only (Cho/NAA and lactate presence that was considered a high grade glioma marker), for perfusional data only (rCBV) and finally for both spectroscopic and perfusional data together. Sensitivity was significantly highest evaluating both spectroscopic and perfusional data together (89.7%) in comparison with spectroscopy (74.4%) or perfusion (79.4%) alone. Instead specificity was slightly lower with all data (91.7%) in comparison with spectroscopy (95.8%) and perfusion (95.8%) alone. In conclusion, to characterize high grade gliomas it is more useful to evaluate spectroscopic and perfusional data together with respect only one of these techniques alone.
MajosCAlonsoJAguileraC. Proton magnetic resonance spectroscopy ((1) H MRS) of human brain tumours: Assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol.2003; 13: 582–591.
5.
HakyemezBErdoganCErcanI. High-grade and low-grade gliomas: Differentiation by using perfusion MR imaging. Clin Radiol.2005; 60: 493–502.
6.
StadlbauerAGruberSNimskyC. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology.2006; 238: 958–969.
7.
CandiniG. A statistical method for the quantification of the learning index by means of multiple answer tests Graduate-Response Test. Comput Biol Med.2004; 34: 663–678.
8.
HouraniRBrantLJRizkT. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and non neoplastic brain lesions in audults?Am J Neuroradiol.2008; 29: 366–372.
9.
LawMChaSKnoppEA. High-grade gliomas and solitary metastases: Differentiation by using perfusion and proton spectroscopic MR imaging. Radiology.2002; 222: 715–721.
10.
Di CostanzoAScarabinoTTrojsiF. Multiparametric 3 T MR approach to the assessment of cerebral gliomas: Tumor extent and malignancy. Neuroradiology.2006; 48: 622–631.
11.
DowlingCBollenAWNoworolskiSM. Preoperative proton MR spectroscopic imaging of brain tumors: Correlation with histopathologic analysis of resection specimens. Am J Neuroradiol.2001; 22: 604–612.
12.
LiXLuYPirzkallA. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging.2002; 16: 229–237.
13.
FanGGDengQLWuZH. Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: A valuable tool to predict tumour grading?Br J Radiol.2006; 79: 652–658.
14.
SugaharaTKorogiYKochiM. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. Am J Roentgenol.1998; 171: 1479–1486.
15.
MaiaACJrMalheirosSMda RochaAJ. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. Am J Neuroradiol.2005: 26: 777–783.
16.
RollinNGuyotatJStreichenbergerN. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology.2006; 48: 150–159.
17.
FulhamMJBizziADietzMJ. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: Clinical relevance. Radiology.1992; 185: 675–686.
18.
PoptaniHGuptaRKRoyR. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. Am J Neuroradiol.1995; 16: 1593–1603.
19.
ShimizuHKumabeTTominagaT. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. Am J Neuroradiol.1996; 17: 737–747.
20.
MagalhaesAGodfreyWShenY. Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol.2005; 12: 51–57.
21.
SugaharaTKorogiYKochiM. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging.1999; 9: 53–60.
22.
KonoKInoueYNakayamaK. The role of diffusion-weighted imaging in patients with brain tumors. Am J Neuroradiol.2001; 22: 1081–1088.
23.
SadeghiND'HaeneNDecaesteckerC. Apparent diffusion coefficient and cerebral blood volume in brain gliomas: Relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. Am J Neuroradiol.2008; 29: 476–482.
24.
ArvindaHRKesavadasCSarmaPS. Glioma grading: Sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol.2009; 94: 87–96.
25.
FayedNModregoPJ. The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. J Neurooncol.2005; 72: 261–265.
26.
RockJPScarpaceLHearshenD. Associations among magnetic resonance spectroscopy, apparent diffusion coefficient, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery. 2004; 54: 1111–1117.
LawMYangSWangH. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol.2003; 24: 1989–1998.
29.
Di CostanzoAScarabinoTTrojsiF. Proton MR spectroscopy of cerebral gliomas at 3T: Spatial heterogeneity, and tumor grade and extent. Eur Radiol.2008; 18: 1727–1735.
30.
ZonariPBaraldiPCrisiG. Multimodal MRI in the characterization of glial neoplasms: The combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging. Neuroradiology.2007; 49: 795–803.
31.
FayedNDavilaJMedranoJ. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI. Eur J Radiol.2008: 67: 427–433.
32.
BatraATripathiRPSinghAK. Perfusion magnetic resonance imaging and magnetic resonance spectroscopy of cerebral gliomas showing imperceptible contrast enhancement on conventional magnetic resonance imaging. Astralas Radiol.2004; 48: 324–332.
33.
XuMSeeSJNgWH. Comparison of magnetic resonance spectroscopy and perfusion weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery. 2004; 56: 919–926.
34.
SpampinatoMVSithJKKwockL. Cerebral bood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. Am J Roetgenol.2007; 188: 204–212.
